Beta lapachone - KT&G Life Sciences

Drug Profile

Beta lapachone - KT&G Life Sciences

Alternative Names: MB-12066

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mazence
  • Developer KT&G Life Sciences
  • Class Antineoplastics; Eye disorder therapies; Naphthoquinones; Obesity therapies; Small molecules
  • Mechanism of Action Sirtuin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-alcoholic fatty liver disease
  • Phase I Macular degeneration
  • No development reported Metabolic syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Metabolic-syndrome(In volunteers) in South Korea (PO, Tablet)
  • 31 Mar 2015 KT&G Life Sciences terminates phase II trial in Non-alcoholic fatty liver disease in South Korea (NCT02029586) before March 2015
  • 01 Feb 2015 KT&G Life Sciences completes a phase I trial in Healthy volunteers in South Korea (NCT02338856)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top